Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Partnered Content
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Companies Manufacturing Compliance

Manufacturing Roundup – 1 April 2019

  • News

Executive Summary

Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.

You may also be interested in...



Zydus Cadila Gets Warning Letter

Zydus Cadila has received a warning letter from the FDA for its Moraiya facility. The company has insisted that it will not affect the existing business in the US where it has filed over 330 ANDAs.

Alkem Grows At Home And Abroad

Alkem said it had a “mixed year”, registering growth in India and internationally despite setbacks that included a weak anti-infectives season and a recent Form 483 from the US Food and Drug Administration.

Manufacturing Round-Up: Sterling Gains A US Site As Normon Invests €100m

Sterling Pharma Solutions has acquired a US facility and Olon has bought a plant from Sandoz, while Normon is investing €100m in manufacturing expansions.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Tags:
Companies Manufacturing Compliance
UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By